SOST and osteogenesis imperfecta: Considering that cardiovascular abnormalities are associated secondary features of OI patients, an increasing cardiovascular risk is foreseeable for OI patients during sclerostin antibody treatment, especially for those with history of cardiovascular diseases 1, 9, 10.